Celcuity Set to Reveal Important Results from VIKTORIA-1 Trial
Celcuity Inc. (NASDAQ: CELC), known for its cutting-edge work in biotechnology, is preparing to announce the topline results from its PIK3CA Wild-Type Cohort as part of the pivotal Phase 3 VIKTORIA-1 trial. This event is highly anticipated in the oncology community, with many looking forward to its implications in treating HR+/HER2- advanced breast cancer.
Details for the Conference Call
The company has scheduled a conference call and webcast for participants to hear the results directly from the management team. This event will take place at 8:00 AM ET. Engaging with such pivotal results often provides insight into future clinical directions, and many healthcare professionals and investors are eager to learn about Celcuity's findings.
Joining the Live Webcast
Individuals interested in joining this live discussion can easily access the webcast. Furthermore, an opportunity to register for the teleconference is available, affording participants a chance to pose questions related to the results. After the live session, a replay will be made available on Celcuity's official website, catering to those who cannot attend in real time.
Understanding Celcuity's Innovative Research
Celcuity is at the forefront of developing targeted therapies designed specifically to tackle various forms of cancer. The company focuses on personalized medicine to improve patient outcomes. One of its leading candidates, gedatolisib, is a powerful pan-PI3K and mTORC1/2 inhibitor that has shown distinct effects on the PAM pathway, setting it apart from other treatments that typically target PI3K?, AKT, or mTORC1.
The VIKTORIA-1 Trial Explained
The ongoing VIKTORIA-1 trial is evaluating the efficacy of gedatolisib when used in combination with the hormone therapy fulvestrant, with potential inclusion of palbociclib. These trials represent significant steps in addressing HR+/HER2- advanced breast cancer, a condition that remains challenging to treat effectively.
Ongoing Research and Additional Trials
As part of its commitment to advancing oncology treatments, Celcuity is also conducting the Phase 1/2 CELC-G-201 trial. This trial explores the combination of gedatolisib and darolutamide in patients battling metastatic castration-resistant prostate cancer. The company further aims to assess gedatolisib plus a CDK4/6 inhibitor along with fulvestrant in an additional Phase 3 study, VIKTORIA-2, providing expansive opportunities for innovation in cancer therapy.
Insights into Celcuity's Mission
Headquartered in Minneapolis, Celcuity is dedicated to transforming the landscape of oncology through its rigorous clinical programs. Its focus on bringing tailored treatments to patients showcases its innovative approach toward combating solid tumors. By addressing unique pathways and employing precise strategies, Celcuity aims to enhance the therapeutic landscape.
Frequently Asked Questions
What is the VIKTORIA-1 trial?
The VIKTORIA-1 trial is a Phase 3 clinical study evaluating the efficacy of gedatolisib in combination with fulvestrant, and potentially palbociclib, for treating HR+/HER2- advanced breast cancer.
When will the topline results be announced?
Celcuity will share the topline results during a conference call on a specified date at 8:00 AM ET.
How can I attend the conference call?
Participants can access the conference call and webcast through Celcuity’s official channels, with a replay available afterward on their website.
What other clinical trials are Celcuity pursuing?
In addition to the VIKTORIA-1 trial, Celcuity is also involved in the CELC-G-201 trial for prostate cancer and VIKTORIA-2 trial for frontline treatment of HR+/HER2- breast cancer.
Who can I contact for more information?
For further inquiries, interested individuals can reach out to Brian Sullivan or Vicky Hahne through their official emails. Celcuity’s contact information is readily available on their website.
